- Home
- QQQX vs MDXG Comparison
QQQX vs MDXG Comparison
Compare QQQX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QQQX
- MDXG
- Stock Information
- Founded
- QQQX 2007
- MDXG 2006
- Country
- QQQX United States
- MDXG United States
- Employees
- QQQX N/A
- MDXG N/A
- Industry
- QQQX Finance Companies
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- QQQX Finance
- MDXG Health Care
- Exchange
- QQQX Nasdaq
- MDXG Nasdaq
- Market Cap
- QQQX 1.2B
- MDXG 1.1B
- IPO Year
- QQQX N/A
- MDXG N/A
- Fundamental
- Price
- QQQX $25.76
- MDXG $9.22
- Analyst Decision
- QQQX
- MDXG Strong Buy
- Analyst Count
- QQQX 0
- MDXG 5
- Target Price
- QQQX N/A
- MDXG $12.00
- AVG Volume (30 Days)
- QQQX 127.6K
- MDXG 1.1M
- Earning Date
- QQQX 01-01-0001
- MDXG 10-30-2024
- Dividend Yield
- QQQX 7.03%
- MDXG N/A
- EPS Growth
- QQQX N/A
- MDXG N/A
- EPS
- QQQX N/A
- MDXG 0.52
- Revenue
- QQQX N/A
- MDXG $342,804,000.00
- Revenue This Year
- QQQX N/A
- MDXG $9.56
- Revenue Next Year
- QQQX N/A
- MDXG $9.19
- P/E Ratio
- QQQX N/A
- MDXG $17.84
- Revenue Growth
- QQQX N/A
- MDXG 10.93
- 52 Week Low
- QQQX $20.27
- MDXG $5.47
- 52 Week High
- QQQX $25.99
- MDXG $9.49
- Technical
- Relative Strength Index (RSI)
- QQQX 52.47
- MDXG 79.76
- Support Level
- QQQX $25.60
- MDXG $8.55
- Resistance Level
- QQQX $26.33
- MDXG $9.49
- Average True Range (ATR)
- QQQX 0.28
- MDXG 0.42
- MACD
- QQQX -0.04
- MDXG 0.17
- Stochastic Oscillator
- QQQX 59.86
- MDXG 89.66
About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.